Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits?

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Vascular Biology

Background:

• Therapeutic angiogenesis aims to restore blood supply to ischemic tissues like the myocardium and skeletal muscles.
• Despite preclinical success, clinical trials using proangiogenic factors for myocardial infarction and leg ischemia have yielded disappointing results.
• A significant gap exists between the efficacy observed in animal models and the lack of clinical benefit in human patients.

Purpose of the Study:

• To investigate the reasons behind the failure of clinical angiogenesis trials.
• To identify the discrepancies between animal models and human patients in the context of therapeutic angiogenesis.
• To explore molecular mechanisms of arteriogenesis and propose improved strategies for functional collateral network formation.

Main Methods:

• Review of molecular mechanisms underlying arteriogenesis.
• Comparative analysis of animal models and human patients in angiogenesis studies.
• Discussion of potential improvements for therapeutic outcomes.

Main Results:

• Clinical translation of proangiogenic therapies has been hindered by factors not fully recapitulated in animal models.
• Understanding the differences between animal models and patients is crucial for designing effective trials.
• Novel approaches focusing on functional collateral networks are needed.

Conclusions:

• The principle of promoting angiogenesis requires re-evaluation for clinical application in ischemic diseases.
• Future strategies must address the complexities of human vascularization and disease pathology.
• Improved trial design and a deeper understanding of arteriogenesis are essential for therapeutic success.